[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100582063":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":27,"centralContacts":31,"locations":18,"responsibleParty":41,"collaborators":18,"id":44,"slug":18,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":45,"sex":51,"minAge":52,"maxAge":18,"enrollmentInfo":53,"targetDuration":18,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":66,"whyStopped":18,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":18},{"fullName":5,"class":6},"Taichung Veterans General Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"study group","EXPERIMENTAL","Patients who are enrolled will be randomly assigned to either the study group. Receiving Canagliflozin 100mg QD before undergoing mechanical thrombectomy. The prescribed duration of Canagliflozin 100mg QD will be 14 days.",[13],"Drug: Canagliflozin 100mg",{"label":15,"type":16,"description":17,"interventionNames":18},"control group","NO_INTERVENTION","Patients who are enrolled will be randomly assigned to either the control group.\n\nNot receiving Canagliflozin before undergoing mechanical thrombectomy.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Canagliflozin 100mg","receiving Canagliflozin 100mg QD",[9],[26],"Canagliflozin",[28],{"name":29,"affiliation":5,"role":30},"Po-Lin Chen","STUDY_DIRECTOR",[32,37],{"name":29,"role":33,"phone":34,"phoneExt":35,"email":36},"CONTACT","+886 23592525","3022","boring@mail2000.com.tw",{"name":38,"role":33,"phone":34,"phoneExt":39,"email":40},"Yu-Hsuan Wu","3096","willie900811@gmail.com",{"type":42,"investigatorFullName":29,"investigatorTitle":43,"investigatorAffiliation":5,"oldNameTitle":18,"oldOrganization":18},"PRINCIPAL_INVESTIGATOR","Director","100582063",false,"NCT06858436","SGLT2 Inhibitor Utilization Re-perfusion Therapy","The Role of SGLT2 Inhibitors in Stroke-reperfusion Injury:A Multi-Center, Randomized, Open-Label, Controlled Trial","SUPER","Inclusion Criteria:\n\n* Patients must have been diagnosed with acute ischemic stroke and large vessel occlusion by a neurologist, with confirmation supported by CT perfusion scans.\n* Patients must be scheduled to undergo mechanical thrombectomy.\n\nExclusion Criteria:\n\n* Patients with have stage 4 or 5 chronic kidney disease (estimated glomerular filtration rate (eGFR) below 30 mL\u002Fmin\u002F1.73 m² on dialysis)\n* Patients with currently taking an SGLT2i or within 3 months prior to enrollment\n* Patients with a known hypersensitivity or allergic reaction to Canagliflozin\n* Patients with type 1 diabetes mellitus\n* Patients with pregnancy or lactation","ALL","18 Years",{"count":54,"type":55},150,"ESTIMATED","INTERVENTIONAL",[58],"PHASE4","Background:\n\nReperfusion therapies, including intravenous rt-PA and mechanical thrombectomy, significantly improve outcomes in acute ischemic stroke. However, these interventions also increase the risk of hemorrhagic transformation and malignant edema. Preclinical studies have demonstrated that Canagliflozin, an SGLT2 inhibitor, reduces astrocyte swelling and brain edema in a transient middle cerebral artery occlusion (tMCAo) model. While SGLT2 inhibitors have shown neuroprotective effects in the acute phase of ischemic stroke, their potential to mitigate hemorrhagic transformation and malignant edema following reperfusion therapy in humans remains unexamined.\n\nAims:\n\nThis study aims to evaluate the effect of SGLT2 inhibitors on hemorrhagic transformation and malignant edema in patients undergoing reperfusion therapy for acute ischemic stroke.\n\nMethods:\n\nThis is a multi-center, randomized, open-label, controlled study enrolling ischemic stroke patients aged 18 years or older who meet predefined inclusion and exclusion criteria. Participants will be randomized to receive Canagliflozin 100 mg once daily for 14 days or no additional treatment before undergoing mechanical thrombectomy. Clinical data collection will include baseline demographics, medical and medication history, NIHSS scores at admission and 24 hours post-reperfusion, stroke subtype, modified Thrombolysis in Cerebral Infarction (TICI) scores, laboratory results, and modified Rankin Scale (mRS) scores at discharge and 3 months post-stroke.\n\nThe primary outcome is to assess the association between Canagliflozin use and the severity of hemorrhagic transformation and malignant edema. Hemorrhagic transformation will be classified using the Heidelberg criteria, and malignant edema will be defined as a midline shift of ≥5 mm. Brain imaging, including CT scans at 24 hours post-intervention and additional scans as clinically indicated, will be reviewed by blinded radiologists. Brain MRA will also be performed to assess infarct size and edema progression.\n\nImportance:\n\nThis study aims to explore the potential for repurposing SGLT2 inhibitors as a therapeutic strategy in acute ischemic stroke. If Canagliflozin is shown to reduce hemorrhagic transformation and malignant edema, it could offer a novel adjunctive treatment to improve patient outcomes following reperfusion therapy.",[61],"Acute Ischemic Stroke From Large Vessel Occlusion",[63,64,65],"reperfusion therapy","SGLT2 inhibitor","malignant edema and transformation hemorrhage","NOT_YET_RECRUITING","2026-03-30",{"date":69,"type":70},"2026-04-03","ACTUAL",{"date":72,"type":55},"2026-04-13",{"date":74,"type":55},"2027-10-31",{"name":5,"class":6}]